Costa-Barbosa Augusto, Pacheco Maria Inês, Gomes Andreia C, Collins Tony, Vilanova Manuel, Pais Célia, Correia Alexandra, Sampaio Paula
Centre of Molecular and Environmental Biology (CBMA) /Aquatic Research Network (ARNET) Associate Laboratory, Universidade do Minho, Campus de Gualtar, Braga, Portugal.
Institute of Science and Innovation for Sustainability (IB-S), Universidade do Minho, Campus de Gualtar, Braga, Portugal.
NPJ Vaccines. 2025 Jun 13;10(1):124. doi: 10.1038/s41541-025-01183-0.
Candida albicans causes systemic infections with 20-50% mortality in critically ill and immunocompromised patients, despite antifungal treatment. Current therapies face limitations, including toxicity and resistance, underscoring the need for prophylactic vaccines. This study presents a novel divalent liposomal vaccine, delivering C. albicans Cht3 and Sap2 antigens. Vaccination induced protective Th1/Th17 immunity, a balanced Th1/Th2 ratio, antigen-specific antibodies, and boosted macrophage activity, improving survival in a mouse model of invasive candidiasis.
白色念珠菌可导致重症和免疫功能低下患者发生全身感染，即便进行抗真菌治疗，死亡率仍为20%-50%。当前的治疗方法存在局限性，包括毒性和耐药性，这凸显了预防性疫苗的必要性。本研究提出了一种新型二价脂质体疫苗，可递送白色念珠菌Cht3和Sap2抗原。接种疫苗可诱导保护性Th1/Th17免疫、平衡的Th1/Th2比例、抗原特异性抗体，并增强巨噬细胞活性，从而提高侵袭性念珠菌病小鼠模型的存活率。
